Does C44.99 require prior authorization?

No, C44.99 does not require prior authorization (high confidence). Covered without prior authorization.

`C44.99`, Other specified malignant neoplasm of skin, unspecified

ICD-10-CM

No Prior Auth Required

Covered without prior authorization (high confidence)

Select and report the appropriate CPT code for the Next-Generation Sequencing for Solid Tumors service.
Enter 1 unit of service (UOS) for the reported CPT code.
Enter the appropriate DEX Z-Code identifier adjacent to the CPT code in the comment/narrative field for Part B electronic claims (Loop 2400 or SV101-7 for 837P) and for Part B paper claims (Box 19).
Enter the appropriate DEX Z-Code identifier adjacent to the CPT code in the comment/narrative field for Part A electronic claims (Line SV202-7 for 837I) and on the UB-04 (Block 80) for Part A paper claims.

Blepharoplasty is covered for blepharochalasis when chronic recurrent eyelid edema has produced excess skin requiring functional repair.
Upper blepharoplasty is considered reconstructive and covered when excess upper eyelid tissue or abnormally low upper lid position produces functional visual complaints (e.g., interference with primary or downgaze reading or superior/lateral visual field loss).
Blepharoplasty is covered for dermatochalasis, including symptomatic redundant skin weighing down on the upper eyelashes and surgically induced dermatochalasis after ptosis repair.
Blepharoptosis repair (ptosis surgery) is covered when aponeurotic dehiscence or other ptosis causes obstruct the superior visual field or visual axis in downgaze (reading position), including dehiscence after trauma or cataract extraction.
Brow ptosis repair is covered when brow ptosis contributes to significant superior visual field loss and brow repair is necessary for adequate functional result (may be done in conjunction with blepharoplasty/ptosis repair).
Blepharoplasty/eyelid surgery is covered to reconstruct anatomical or pathological defects caused by disease (including thyroid dysfunction and cranial nerve palsies), trauma, or tumor-ablative surgery when reconstruction protects the eye or improves visual function.

CGS-J15-L38822, MolDX: Minimal Residual Disease Testing for Cancer

J15

CGS-J15-L33944, Blepharoplasty

J15

CGS-J15-L34356, Erythropoiesis Stimulating Agents (ESA)

J15

CGS-J15-L40225, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer

J15

Ask Backwork about documentation requirements, denial risks, or coverage in your state.